Soochow: AI medical technology accelerates penetration, image market size may exceed 13.7 billion yuan by 2030.

Soochow released a research report stating that AI healthcare is becoming the core drive of transformation in the medical industry. By 2030, the AI healthcare market in China is expected to exceed 150 billion yuan, with significant growth in sub-sectors such as AI imaging, surgical Siasun Robot & Automation, etc. Policy support combined with technological advancements are driving the implementation of AI in disease diagnosis, health management, drug development, and other processes. It is recommended to focus on structural opportunities in areas such as image recognition, pathological diagnosis, and health management. Key points from Soochow: Background and driving factors of AI healthcare development With the development of information technology and artificial intelligence, the application of AI in the healthcare field is accelerating, becoming a key driver of transformation in the medical industry. The progress of AI healthcare relies on a sound digital healthcare system, which ensures the wide collection, standardized storage, and efficient transmission of medical data, providing high-quality data support for AI algorithms. The rise of deep learning and large models further enhances the level of disease diagnosis, risk prediction, and personalized treatment plans. Recently, the combination of generative AI and traditional AI has optimized and innovated medical services. Generative AI not only analyzes existing data but also generates new data, expanding intelligent interaction and dialogue capabilities, making medical services more precise, natural, and efficient. AI has particularly excelled in areas such as medical image analysis, surgical assistance, and disease diagnosis, driving the intelligent, efficient, and convenient development of medical services. AI empowering the entire process of healthcare and the development of sub-sectors AI has been widely applied across the entire healthcare process, including health management, pre-diagnosis, diagnosis, and post-service, image analysis, drug development, and surgical Siasun Robot & Automation, etc. AI assists medical institutions in improving efficiency, optimizing processes, and enhancing patient experiences. Due to rapid growth driven by an aging population and shortage of medical staff, data from the "China AI Healthcare Industry Research Report" shows that the market size will reach 97.3 billion yuan in 2023 and is expected to reach 159.8 billion yuan by 2028. In the sub-sectors, AI imaging, pathology, medical systems, health management, terminal applications, pharmaceuticals, etc., each have their characteristics, with increasing market size, clear competitive landscape, and policy support, showing a positive trend for future development. Special characteristics of AI healthcare sub-sectors AI imaging has seen significant growth due to the pressure on doctors caused by aging demographics and uneven distribution of medical resources, with more certified products under policy support. According to EO Intelligence, the AI imaging market was 2.4 billion yuan in 2023, and is expected to reach 13.74 billion yuan in 2030. Domestic enterprises have shown good results and have various development potentials. In AI medical Siasun Robot & Automation, although in the early stages of development, the future looks promising. The market size was around 7.17 billion yuan in 2023, and EO Intelligence predicts it will reach 18.88 billion yuan by 2025. Multiple brand competitions and the trend of domestic substitution are observed, with differences in medical insurance, equipment certification, and hospital usage affecting each region and mutually influencing each other. AI-empowered CDSS and disease quality control field, CDSS plays a significant role, AIGC helps improve efficiency and forms 7 major systems, policy-level promotion accelerates commercialization, the general market exceeds 10 billion, and the specialist market depends on the enterprises exploration. It is expected to develop deeply toward two directions: in-depth development and content quality control. Although AI health management is in its early stages of development, with broad subfields and government support, market concentration is low, the competitive landscape is unstable, and future demand is expected to expand rapidly. Recommended focus: AI image recognition: Shanghai United Imaging Healthcare: (688271.SH), Beijing Wandong Medical Technology: (600055.SH), Neusoft Corporation: (600718.SH). AI pathological diagnosis: Guangzhou Kingmed Diagnostics Group: (603882.SH), BGI Genomics: (300676.SZ), Dian Diagnostics Group: (300244.SZ). AI healthcare system: Shanghai Runda Medical Technology: (603108.SH). AI health management: Meinian Onehealth Healthcare Holdings: (002044.SZ), Sinocare Inc.: (300298.SZ), Guangdong Transtek Medical Electronics: (300562.SZ), JD HEALTH: (06618), ALI HEALTH: (00241). AI terminal applications: Meinian Onehealth Healthcare Holdings, GUSHENGTANG: (02273), Sanbo Hospital Management: (301293.SZ). AI pharmaceuticals: Crystal Tai Holdings: (02228), PharmaResources: (301230.SZ), Hitgen Inc.: (688222.SH). AI+Genomics: BGI GenomicsMGI Tech Co., Ltd.: (688114.SH), Jiangsu Cowin Biotech: (688426.SH). Risk warning: Technology and algorithm risks, legal and compliance risks, ethical and social risks, data and model risks, etc.